Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Covaris Strike Co-Marketing Pact for Sequencing Techs

NEW YORK (GenomeWeb News) – Agilent Technologies and Covaris have struck a co-marketing agreement for their target enrichment and DNA shearing technologies for next-generation sequencing studies, Agilent said today.

Under the agreement, the Covaris S2 DNA shearing technology will be marketed with Agilent's SureSelect Target Enrichment System to researchers using next-generation sequencing.

The Covaris technology uses the firm's Adaptive Focused Acoustic method for biological and chemical sample preparation, and it provides a "predictable and reproducible" DNA shearing method that can limit the amount of DNA lost in the process, the company said.

As part of the agreement, Covaris has developed a SureSelect Accessory Kit to help integrate the Agilent and Covaris workflows, Agilent said.

The companies will continue to work together to develop new protocols and products for the SureSelect and Covaris S2 systems, the partners added.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more